(Q33729339)

29 July 2017

1 reference

title

New perspectives for asthma treatment: anti-leukotriene drugs (English)

1 reference

29 July 2017

1 reference

García-Marcos L

1

1 reference

29 July 2017

Schuster A

series ordinal

2

1 reference

29 July 2017

publication date

1 May 1999

1 reference

Pediatric Allergy & Immunology

29 July 2017

published in

1 reference

29 July 2017

volume

10

1 reference

29 July 2017

issue

2

1 reference

29 July 2017

page(s)

77-88

1 reference

Liberation of histamine and formation of lysocithin-like substances by cobra venom

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

THE LIBERATION OF A SLOW-REACTING SMOOTH MUSCLE-STIMULATING SUBSTANCE IN ANAPHYLAXIS

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Leukotriene C: a slow-reacting substance from murine mastocytoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Release of leukotrienes in patients with bronchial asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Cysteinyl leukotrienes in asthma: old mediators up to new tricks

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Leukotrienes and airway responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Leukotrienes in the pathogenesis of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Experimental asthma developed by room air contamination with cockroach allergen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

In vitro and in vivo effects of leukotriene B4 antagonism in a primate model of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Dose-dependent mediation of leukotriene D4-induced airway microvascular leakage and bronchoconstriction in the guinea pig

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D4 (LTD4) challenge in normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Worldwide clinical experience with the first marketed leukotriene receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Evening dosing is associated with higher plasma concentrations of pranlukast, a leukotriene receptor antagonist, in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Challenge studies of a leukotriene receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Therapeutic effect of pranlukast, a selective cysteinyl leukotriene receptor antagonist, on bronchial asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Lung function improvement in asthma with a cysteinylleukotriene receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Single dose pharmacokinetics, safety and tolerability of MK-0476, a new leukotriene D4-receptor antagonist, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

The Pivotal Role of 5-Lipoxygenase Products in the Reaction of Aspirin-sensitive Asthmatics to Aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

Leukotriene receptor antagonists: clinical effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

Challenge interval determines tachyphylaxis to aerosolized LTD4

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

Urinary leukotriene E4 levels in patients with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

Exercise-Induced Urinary Excretion of Leukotriene E4 in Children with Atopic Asthma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

The effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileuton

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

Effect of zileuton on theophylline pharmacokinetics

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

Pharmacokinetic interactions between zileuton and prednisone

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

The pharmacokinetics of zileuton in healthy young and elderly volunteers.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

The effect of food on the pharmacokinetics of zileuton.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

Pharmacokinetics of zileuton and its metabolites in patients with renal impairment

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

Results of the first U.S. double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

The single and multiple dose pharmacokinetics of pranlukast in healthy volunteers

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

Inhibition of platelet-activating factor-induced bronchoconstriction by the leukotriene D4 receptor antagonist ICI 204,219

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3038.1999.00006.X

7 January 2021

10.1034/J.1399-3038.1999.00006.X

Identifiers

DOI

1 reference

29 July 2017

1 reference